Roche says flexible pricing ready for cancer, not MS drugs | Reuters
▻http://uk.reuters.com/article/us-roche-novartis-pricing-ms-idUKKBN132159
new data-driven flexible pricing schemes the Swiss drugmaker and others in the industry are pushing to replace today’s “pay-per-pill” approach are well advanced in cancer treatment (…)
Such schemes foresee drug pricing based on measurable benefits for a patient or health care systems, an approach seen as becoming more important as aging populations and chronic disease put the squeeze on health care systems.
Roche has introduced flexible pricing for cancer drugs in about a dozen European countries, including Italy, Belgium, Hungary, Switzerland and Austria. For instance, it already prices drugs like Avastin differently in some markets depending on the cancer being targeted.